Abstract
Cancer remains one of the leading causes of morbidity and mortality worldwide, with low- and middle-income countries (LMICs) disproportionately affected due to limited access to essential cancer products. Despite rapid advances in cancer diagnostics, therapeutics, and supportive care, significant disparities persist in the availability, affordability, and quality of these products across different regions. This inequity contributes to delayed diagnosis, suboptimal treatment, and poorer survival outcomes for millions of patients in resource-constrained settings. Addressing the complex and multifactorial barriers ranging from high drug prices, inadequate supply chains, regulatory hurdles, to weak health systems is critical to advancing global cancer control efforts. This article provides a comprehensive overview of these challenges and outlines evidence-based strategies such as pooled procurement, local manufacturing, regulatory harmonization, integration into universal health coverage (UHC), and capacity building to promote equitable access. Achieving equity in access to cancer products is essential to reduce global cancer disparities, improve patient outcomes, and fulfill international commitments such as the Sustainable Development Goals (SDGs).
Introduction
Cancer is a major public health challenge, with an estimated 19.3 million new cases and nearly 10 million deaths worldwide in 2020 alone (Sung et al., 2021). While cancer affects populations globally, the burden is not evenly distributed. Low- and middle-income countries (LMICs) experience a growing share of the cancer burden, accounting for over 70% of cancer deaths despite representing less than 60% of the global population (WHO, 2020). These countries often face the double burden of infectious diseases and rising non-communicable diseases, including cancer, straining already fragile health systems.
One of the most significant contributors to poor cancer outcomes in LMICs is the lack of equitable access to essential cancer products ranging from diagnostic tools and imaging technologies to chemotherapy drugs, targeted therapies, immunotherapies, vaccines, and supportive care medications. Without timely and affordable access to these products, patients face delays in diagnosis, interruptions in treatment, and limited options for curative or palliative care. This situation not only worsens individual patient outcomes but also increases the overall societal and economic burden of cancer.
Equitable access means more than just physical availability; it encompasses affordability, quality, acceptability, and timely delivery of cancer products to all populations, regardless of socioeconomic status, geography, or health infrastructure (WHO, 2020). The challenge is complex, involving pharmaceutical pricing policies, supply chain logistics, regulatory systems, health workforce capacity, and integration of cancer care into universal health coverage (UHC) frameworks.
Addressing these multifaceted barriers is imperative to achieving the Sustainable Development Goals (SDGs), particularly SDG 3.4, which targets a one-third reduction in premature mortality from non-communicable diseases, including cancer, by 2030 (United Nations, 2015). Moreover, improving equitable access aligns with the principles of health equity and social justice, emphasizing that all individuals should have a fair opportunity to attain their full health potential.
This article explores the key barriers impeding equitable access to cancer products in LMICs and highlights strategic interventions and global initiatives designed to bridge these gaps. By understanding and addressing these challenges, stakeholders can make meaningful progress toward a future where high-quality cancer care is accessible and affordable for all.
Barriers to Equitable Access
High Costs and Pricing Inequities
Cancer drugs, especially novel agents such as immune checkpoint inhibitors and targeted therapies, often come with exorbitant prices. For example, a course of immunotherapy may cost tens of thousands of US dollars per patient annually (Sarfaty et al., 2018). Patents and intellectual property rights limit generic competition, keeping prices high. Additionally, pharmaceutical companies often use differential pricing strategies that may not sufficiently address affordability in LMICs (Vogler et al., 2020). The result is that many patients in resource-constrained settings cannot access life-saving treatments, exacerbating survival disparities.
Supply Chain and Distribution Challenges
Weaknesses in supply chain management are a major barrier in LMICs. This includes inadequate cold-chain infrastructure, unreliable transportation networks, poor inventory management, and frequent stockouts of essential cancer medicines and diagnostics (Mackey et al., 2018). These challenges disrupt continuous treatment, which is critical for cancer control, and contribute to poor patient outcomes.
Limited Local Manufacturing Capacity
Most LMICs rely heavily on imported cancer medicines and diagnostics, increasing costs and vulnerability to global supply disruptions (Garde et al., 2021). The absence of local pharmaceutical manufacturing capabilities means these countries are subject to international market fluctuations, regulatory delays, and logistical hurdles that impede consistent access.
Regulatory and Policy Barriers
Lengthy and fragmented regulatory approval processes delay access to new cancer products. Many countries lack harmonized regulatory frameworks, causing duplication and inefficiencies (Ndomondo-Sigonda et al., 2021). Moreover, the absence of comprehensive national cancer control plans that integrate access to medicines and diagnostics further impairs equitable distribution.
Health System Constraints
Cancer care requires an integrated approach involving trained healthcare professionals, diagnostic laboratories, and treatment facilities. Many LMIC health systems suffer from workforce shortages, inadequate infrastructure, and limited integration of cancer care into primary health services (Farmer et al., 2019). These factors limit the effective utilization of available cancer products, even when they are physically present.
Strategies to Promote Equitable Access
Price Negotiation and Pooled Procurement
Countries and regional blocs can pool demand and negotiate prices collectively, leveraging greater bargaining power to reduce costs (Wirtz et al., 2017). Initiatives like the Pan American Health Organization’s Strategic Fund and the African Medicines Agency’s proposed procurement frameworks exemplify successful approaches to increase affordability and supply security (Danzon & Towse, 2019).
Local Production and Technology Transfer
Investing in local pharmaceutical manufacturing through technology transfer agreements and capacity-building programs can reduce dependency on imports, lower costs, and improve supply resilience (Bates et al., 2020). Africa’s growing pharmaceutical manufacturing hubs in South Africa, Egypt, and Kenya show promising progress but require further support to produce oncology products at scale.
Strengthening Supply Chains
Improving logistics infrastructure, inventory management systems, and cold chain capacity are critical steps to ensure the availability of cancer medicines and diagnostics at points of care (Yadav, 2015). Digital supply chain management tools can increase transparency and reduce wastage.
Regulatory Harmonization and Fast-Track Approvals
Regional regulatory harmonization, such as through the African Medicines Regulatory Harmonization (AMRH) initiative, can streamline approvals, reduce duplication, and accelerate access to essential cancer products (Kapungu et al., 2019). Fast-track approval pathways for priority oncology medicines are also vital to reduce delays.
Integration into Universal Health Coverage (UHC)
Incorporating cancer diagnostics and treatments into UHC packages protects patients from catastrophic health expenditures and widens access (WHO, 2021). Governments need to prioritize cancer within national health plans and allocate sufficient funding to oncology services.
Capacity Building and Health System Strengthening
Training oncology healthcare professionals, upgrading laboratory and treatment infrastructure, and embedding cancer services into primary healthcare improve the delivery of cancer care (Mukherjee et al., 2019). Task-shifting and telemedicine may extend reach to rural and underserved populations.
Role of Global Partnerships and Initiatives
Collaborative efforts by WHO, the Union for International Cancer Control (UICC), the African Union, and philanthropic organizations are instrumental in closing access gaps. The WHO’s Model List of Essential Medicines (EML) guides countries in prioritizing cancer drugs, and initiatives like the Access to COVID-19 Tools Accelerator (ACT-A) provide lessons on equitable access that can be applied to oncology (WHO, 2021). Programs to scale HPV vaccine coverage have successfully demonstrated how partnerships can reduce the incidence of vaccine-preventable cancers (Bruni et al., 2019).
Conclusion
Equitable access to cancer products is fundamental to reducing global disparities in cancer outcomes. Addressing financial, regulatory, supply chain, and systemic barriers requires a coordinated, multi-sectoral response involving governments, manufacturers, civil society, and international organizations. Leveraging pooled procurement, local manufacturing, regulatory harmonization, UHC integration, and health system strengthening can collectively improve cancer product accessibility and affordability. The urgency to act has never been greater, as cancer incidence continues to rise globally, threatening progress toward global health equity.
References
- Bates, M., et al. (2020). Local production of pharmaceuticals in Africa: Needs, opportunities and challenges. BMJ Global Health, 5(12), e002615. https://doi.org/10.1136/bmjgh-2020-002615
- Bruni, L., et al. (2019). Global estimates of human papillomavirus vaccination coverage by region and income level: A pooled analysis. The Lancet Global Health, 7(6), e761–e769. https://doi.org/10.1016/S2214-109X(19)30099-0
- Danzon, P. M., & Towse, A. (2019). Differential pricing for pharmaceuticals: Reconciling access, R&D and patents. International Journal of Health Economics and Management, 19(3), 209–222. https://doi.org/10.1007/s10754-019-09266-3
- Farmer, P. E., et al. (2019). Cancer care delivery in resource-poor settings. CA: A Cancer Journal for Clinicians, 69(4), 279–292. https://doi.org/10.3322/caac.21562
- Garde, D., et al. (2021). Local production of medicines and health products in low-income and middle-income countries: Barriers and opportunities. The Lancet Global Health, 9(7), e890–e897. https://doi.org/10.1016/S2214-109X(21)00144-1
- Kapungu, C., et al. (2019). Harmonization of regulatory processes for medical products in Africa: Opportunities and challenges. Clinical Therapeutics, 41(8), 1564–1575. https://doi.org/10.1016/j.clinthera.2019.06.011
- Mackey, T. K., et al. (2018). Ensuring access to essential medicines and vaccines in developing countries: A supply chain perspective. Health Policy and Planning, 33(6), 762–771. https://doi.org/10.1093/heapol/czy029
- Mukherjee, S., et al. (2019). Strengthening health systems for cancer care in LMICs. The Lancet Oncology, 20(2), e123–e130. https://doi.org/10.1016/S1470-2045(18)30769-9
- Ndomondo-Sigonda, M., et al. (2021). The African Medicines Regulatory Harmonization initiative: Progress and challenges. Therapeutic Innovation & Regulatory Science, 55(3), 569–576. https://doi.org/10.1007/s43441-020-00232-0
- Sarfaty, M., et al. (2018). The high cost of cancer drugs: Global solutions for affordability. JAMA Oncology, 4(10), 1415–1416. https://doi.org/10.1001/jamaoncol.2018.2047
- Sung, H., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
- United Nations. (2015). Transforming our world: The 2030 agenda for sustainable development. https://sdgs.un.org/2030agenda
- Vogler, S., et al. (2020). Pharmaceutical pricing and reimbursement policies in low- and middle-income countries: A review of current frameworks. Expert Review of Pharmacoeconomics & Outcomes Research, 20(1), 69–78. https://doi.org/10.1080/14737167.2020.1712434
- Wirtz, V. J., et al. (2017). Essential medicines for universal health coverage. The Lancet, 389(
Post a Comment
Full Name :
Adress:
Contact :
Comment: